Oscar Health Stock News

Shares of Coupang and Oscar Health have good chances of bouncing back in 2026. Improved profit margins for the e-commerce giant should continue into 2026.

In this video, I will discuss two undervalued companies that have experienced a decent pullback in 2025 and expect to show fundamental improvements in 2026. Watch the short video to learn more, consider subscribing, and click the special offer link below.

Oscar Health's (OSCR +1.31%) management team is planning big price increases in 2026 to offset higher costs.

Oscar Health is rerated as a bullish pick, driven by ACA enrollment expansion into Alabama, Southern Florida, and other high-growth regions. OSCR projects a 2027 market reach of 24 million members without subsidies and 31 million with subsidies, supporting robust revenue growth. Despite regulatory uncertainty around ACA subsidies expiring after 2025, OSCR's expansion, affordable plans, and inno...

Oscar Health faces ACA subsidy expiration, but aggressive repricing and ICHRA expansion support a contrarian investment thesis. Analysts project FY26 revenue of $12.6bn despite anticipated 10–20% ACA enrollment declines, driven by premium hikes offsetting volume loss and stabilizing MLR. Management's target of 2027 EPS of $2.25 and 5% operating margin implies a forward P/E of 7.6x and EV/EBIT o...

Oscar Health is facing pressures in 2025, but these should reverse in 2026. Investors are not looking at how cheap the stock may be when it returns to profitability in 2026.

Health insurance company stocks rose again Wednesday before the Thanksgiving holiday amid hope the Trump administration and Congress can agree on an extension of tax credits for those who buy individual coverage under the Affordable Care Act.

Shares of Oscar Health (OSCR) jumped Wednesday, the latest big gain for the health insurer after Piper Sandler analysts upgraded their rating of the stock in a recent note to clients.